A Review of the Dermatologic Symptoms of Idiopathic Mast Cell Activation Syndrome

February 2019 | Volume 18 | Issue 2 | Original Article | 162 | Copyright © February 2019

Azam A. Qureshi BAa and Adam J. Friedman MDb,c

aUniversity of Maryland School of Medicine, Baltimore, MD bDepartment of Dermatology, George Washington Medical Faculty Associates, Washington, DC cGeorge Washington School of Medicine and Health Sciences, Washington, DC

ing, urticaria, and angioedema. Allergy Asthma Proc. 2015;36(3):230-233. doi:10.2500/aap.2015.36.3836.39. Van den Poel B, Kochuyt A-M, Del Biondo E, et al. Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients. Acta Clin Belg. 2017;72(2):123-129. doi:10.1080/17843286.2017.1293312.40. Weinstock LB, Brook JB, Myers TL, Goodman B. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Rep. 2018;2018:bcr-2017-221405. doi:10.1136/bcr-2017-221405.41. Álvarez-Twose I, González de Olano D, Sánchez-Muñoz L, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol. 2010;125(6). doi:10.1016/j.jaci.2010.02.019.42. Seidel H, Molderings GJ, Oldenburg J, et al. Bleeding diathesis in patients with mast cell activation disease. Thromb Haemost. 2011;106(5):987-989. doi:10.1160/TH11-05-0351.43. Luzgina NG, Potapova O V, Shkurupiy VA. Structural and functional peculiarities of mast cells in undifferentiated connective tissue dysplasia. Bull Exp Biol Med. 2011;150(6):676-678. http://www.ncbi.nlm.nih.gov/pubmed/22235414. Accessed December 24, 2017.44. Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48(12):1564-1569. doi:10.1038/ng.3696.45. Lyons JJ, Sun G, Stone KD, et al. Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities. J Allergy Clin Immunol. 2014;133(5):1471-1474. doi:10.1016/j.jaci.2013.11.039.46. Kanbe N, Tanaka A, Kanbe M, Itakura A, Kurosawa M, Matsuda H. Human mast cells produce matrix metalloproteinase 9. Eur J Immunol. 1999;29(8): 2645-2649.doi:10.1002/(SICI)1521-4141(199908)29:08 3.0.CO;2-1.47. Kimata M, Ishizaki M, Tanaka H, Nagai H, Inagaki N. Production of matrix metalloproteinases in human cultured mast cells: involvement of protein kinase C-mitogen activated protein kinase kinase-extracellular signal-regulated kinase pathway. Allergol Int. 2006;55(1):67-76. doi:10.2332/allergolint.55.67.48. Matsumoto KI, Minamitani T, Orba Y, Sato M, Sawa H, Ariga H. Induction of matrix metalloproteinase-2 by tenascin-X deficiency is mediated through the c-Jun N-terminal kinase and protein tyrosine kinase phosphorylation pathway. Exp Cell Res. 2004;297(2):404-414. doi:10.1016/j.yexcr.2004.03.041.49. Zweers MC, Hakim AJ, Grahame R, Schalkwijk J. Joint hypermobility syndromes: The pathophysiologic role of tenascin-X gene defects. Arthritis Rheum. 2004;50(9):2742-2749. doi:10.1002/art.20488.50. Vergnolle N, Bunnett NW, Sharkey KA, et al. Proteinase-activated receptor- 2 and hyperalgesia: A novel pain pathway. Nat Med. 2001;7(7):821-826. doi:10.1038/89945.51. Vergnolle N, Hollenberg MD, Sharkey KA, Wallace JL. Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol. 1999;127(5):1083-1090. doi:10.1038/ sj.bjp.0702634.52. Schmidlin F, Amadesi S, Dabbagh K, et al. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol. 2002;169(9):5315-5321. http://www.ncbi.nlm.nih. gov/pubmed/12391252. Accessed February 20, 2018.53. Kaneider NC, Agarwal A, Leger AJ, Kuliopulos A. Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med. 2005;11(6):661-665. doi:10.1038/nm1245.54. Sevigny LM, Zhang P, Bohm A, et al. Interdicting protease-activated receptor- 2-driven inflammation with cell-penetrating pepducins. Proc Natl Acad Sci. 2011;108(20):8491-8496. doi:10.1073/pnas.1017091108.55. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005;120(3):303-313. doi:10.1016/j. cell.2004.12.018.56. Trivedi V, Boire A, Tchernychev B, et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell. 2009;137(2):332-343. doi:10.1016/j.cell.2009.02.018.57. Molino M, Barnathan ES, Numerof R, et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem. 1997;272(7):4043- 4049. http://www.ncbi.nlm.nih.gov/pubmed/9020112. Accessed February20, 2018.58. Noorbakhsh F, Tsutsui S, Vergnolle N, et al. Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med. 2006;203(2):425-435. doi:10.1084/ jem.20052148.59. Cenac N, Coelho AM, Nguyen C, et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol.2002;161(5):1903-1915. doi:10.1016/S0002-9440(10)64466-5.60. Afrin L. Presentation, diagnosis, and management of mast cell activation syndrome. In: Mast Cells. ; 2013:Chapter 6. doi:10.1146/annurev.immunol. 21.120601.141110.61. Fukuyama T, Martel BC, Linder KE, Ehling S, Ganchingco JR, Bäumer W. Hypochlorous acid is antipruritic and anti-inflammatory in a mouse model of atopic dermatitis. Clin Exp Allergy. 2018;48(1):78-88. doi:10.1111/cea.13045.62. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous Acid Generated by Myeloperoxidase Modifies Adjacent Tryptophan and Glycine Residues in the Catalytic Domain of Matrix Metalloproteinase-7 (Matrilysin). J Biol Chem. 2003;278(31):28403-28409. doi:10.1074/jbc.M304739200.63. Stechmiller J, Cowan L, Schultz G. The Role of Doxycycline as a Matrix Metalloproteinase Inhibitor for the Treatment of Chronic Wounds. Biol Res Nurs. 2010;11(4):336-344. doi:10.1177/1099800409346333.64. Tae H-J, Marshall S, Zhang J, Wang M, Briest W, Talan MI. Chronic Treatment with a Broad-Spectrum Metalloproteinase Inhibitor, Doxycycline, Prevents the Development of Spontaneous Aortic Lesions in a Mouse Model of Vascular Ehlers-Danlos Syndrome. J Pharmacol Exp Ther. 2012;343(1):246-251. doi:10.1124/jpet.112.197020.65. Ahmad N, Mukhtar H. Cytochrome p450: a target for drug development for skin diseases. J Invest Dermatol. 2004;123(3):417-425. doi:10.1111/j.0022- 202X.2004.23307.x.66. Ogawa K, Shichishima A, Ikeda K, et al. [Systemic mastocytosis with coagulation abnormalities and gastrointestinal symptoms]. Nihon Naika Gakkai Zasshi. 2009;98(1):141-143. http://www.ncbi.nlm.nih.gov/ pubmed/19227918. Accessed January 6, 2018.67. Afrin LB. Burning mouth syndrome and mast cell activation disorder. Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology. 2011;111(4):465- 472. doi:10.1016/j.tripleo.2010.11.030.68. Afrin LB. Mast cell activation syndrome masquerading as agranulocytosis. Mil Med. 2012;177(1):113-117. http://www.ncbi.nlm.nih.gov/pubmed/22338992. Accessed December 24, 2017.69. Asawa A, Simpson KH, Bonds RS. Ketotifen use in a patient with fire ant hypersensitivity and mast cell activation syndrome. Ann Allergy Asthma Immunol. 2015;114(6):443-446. doi:10.1016/j.anai.2015.03.009.70. Richter EW, Hsu K-L, Moll V. Successful Management of a Patient With Possible Mast Cell Activation Syndrome Undergoing Pulmonary Embolectomy:A Case Report. A A


Adam J. Friedman MD ajfriedman@mfa.gwu.edu